Karyopharm Therapeut
(KPTI)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -34,126 | -165,291 | -126,785 | -90,461 | -41,399 |
| Depreciation Amortization | -635 | 608 | 749 | 655 | 420 |
| Accounts receivable | 11,886 | -5,084 | -4,949 | -982 | -2,495 |
| Accounts payable and accrued liabilities | 6,272 | 1,170 | -790 | 91 | 1,837 |
| Other Working Capital | 10,458 | -19,989 | -25,898 | -26,960 | -25,552 |
| Other Operating Activity | -12,765 | 39,032 | 34,962 | 23,316 | 7,992 |
| Operating Cash Flow | $-18,910 | $-149,554 | $-122,711 | $-94,341 | $-59,197 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -118 | -118 | -79 | -79 |
| Purchase Of Investment | -60,332 | -226,016 | -128,918 | -99,020 | -35,540 |
| Sale Of Investment | 27,944 | 121,878 | 90,078 | 48,468 | 21,584 |
| Investing Cash Flow | $-32,388 | $-104,256 | $-38,958 | $-50,631 | $-14,035 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 193,738 | 37,895 | 32,096 | 30,783 |
| Financing Cash Flow | $N/A | $193,738 | $37,895 | $32,096 | $30,783 |
| Exchange Rate Effect | -45 | -488 | -614 | -544 | -90 |
| Beginning Cash Position | 136,885 | 197,445 | 197,445 | 197,445 | 197,445 |
| End Cash Position | 85,542 | 136,885 | 73,057 | 84,025 | 154,906 |
| Net Cash Flow | $-51,343 | $-60,560 | $-124,388 | $-113,420 | $-42,539 |
| Free Cash Flow | |||||
| Operating Cash Flow | -18,910 | -149,554 | -122,711 | -94,341 | -59,197 |
| Capital Expenditure | N/A | -118 | -118 | -79 | -79 |
| Free Cash Flow | -18,910 | -149,672 | -122,829 | -94,420 | -59,276 |